Development of hypertriglyceridemia due to GPIHBP1 autoantibodies prior to clinical diagnosis of systemic lupus erythematosus in a 14-year-old girl

• Published in: Allergology International Vol. 71; no. 4; pp. 555 - 557
• Main Authors: Kunitsu, Tomoaki, Harada-Shiba, Mariko, Sato, Tomomi, Nonomura, Kazuo, Kimura, Takao, Miyashita, Kazuya, Nakajima, Katsuyuki, Murakami, Masami
• Format: Journal Article
• Language: English; Japanese
• Published: England Elsevier B.V 01.10.2022; JAPANESE SOCIETY OF ALLERGOLOGY; Elsevier
• ISSN: 1323-8930; 1440-1592
• DOI: 10.1016/j.alit.2022.05.001

Dear Editor, Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) is a glycolipid-anchored protein expressed on capillary endothelial cells. It binds and transports lipoprotein lipase (LPL) to its site of action in the capillary lumen. Recently, homozygous pathogenic mutations in GPIHBP1 have been reported to cause severe lifelong hypertriglyceridmia. GPIHBP1 autoantibodies have been shown to cause hypertriglyceridemia by preventing the binding of GPIHBP1 to LPL and are sometimes associated with the development of autoimmune diseases such as systemic lupus erythematosus (SLE). Here, we report the case of a female with hypertriglyceridemia due to GPIHBP1 autoantibodies before the diagnosis of SLE. A 14-year-old girl presented with recurrent upper abdominal pain after eating on day X-14 months. She had been suffering from this symptom for 1 year. Physical examination revealed that she was lean (weight, 49 kg) and had a normal height (165.0 cm) with a body mass index of 18 kg/m2.